Mariana Oncology

Mariana Oncology is a fully integrated biotechnology company specializing in the development of precision radiopharmaceuticals, which are designed to target and deliver radiation to specific tumor sites. The company's mission is to transform cancer care by creating a new standard of care that leverages the power of precisely delivered radiation to treat cancer's toughest tumors. Mariana Oncology's approach combines rational drug design with an in-depth understanding of tumor target biology, allowing for the development of highly targeted radiopharmaceuticals that maximize tumor penetration while minimizing toxicity.

Mariana Oncology has developed a robust pipeline of novel peptide-based radiopharmaceuticals that target a broad spectrum of solid tumor cancers. The company is comprised of some of the world's leading experts in radiopharmaceutical science and manufacturing, and its lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer. The company has raised significant capital through a Series B financing and a Series A investment, which has allowed them to advance their pipeline and transition into a clinical-stage company.

Mariana Oncology is committed to cultivating and developing its workforce by offering a variety of benefits designed to support both personal and professional growth. These benefits include mentoring, skill-building programs, and career path mapping, enabling employees to thrive in their roles. The company also emphasizes creating a positive and supportive work environment, where employees feel valued and empowered to make a real difference in the fight against cancer.

Mariana Oncology is a biotechnology company committed to developing innovative radiopharmaceutical therapies for cancer. Their mission is to revolutionize cancer care by harnessing the power of precision radiopharmaceuticals, creating a future where these drugs are integrated into mainstream treatment. They aim to transform the treatment of solid tumors by developing targeted peptide-based radiopharmaceuticals that maximize tumor penetration while minimizing toxicity.

Mariana Oncology cultivates a culture of innovation and collaboration, driven by a shared passion for developing breakthrough radiopharmaceutical therapies to improve cancer care. They prioritize the development of their employees through mentoring, skill-building, and career path mapping, fostering a supportive and positive work environment. Their emphasis on building self-sustaining teams reflects a commitment to empowering individuals and fostering a sense of shared ownership and responsibility in their mission to conquer cancer's toughest tumors.

Mariana Oncology is committed to fostering a diverse, equitable, and inclusive workplace. Their approach prioritizes creating a culture where all employees feel valued, respected, and empowered to contribute their unique perspectives. This commitment is demonstrated through their recruitment efforts, employee development programs, and initiatives that support diversity and inclusion across the organization. Mariana Oncology is dedicated to creating a workplace where individuals from all backgrounds can thrive and contribute to their mission of revolutionizing cancer care with precision radiopharmaceuticals.